Skip to content
lifestyle.celebhomes.net
Home
Sample Page
Author:
Abivax
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
July 1, 2026
Abivax Announces Launch of Public Offering of American Depositary Shares
June 30, 2026
Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative Colitis Patients and Strengthening the Phase 3 Maintenance Safety Database
June 29, 2026
Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis
June 2, 2026
Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis
May 26, 2026
Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis
May 26, 2026
Abivax Announces Results of its May 11, 2026 Annual General Meeting
May 11, 2026
Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares
May 5, 2026
Abivax to Present Data on Obefazimod at Digestive Disease Week®
April 22, 2026
Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents
April 20, 2026
1
2
Next Page
→